Skip to main content
. 2020 Oct 21;7(6):e903. doi: 10.1212/NXI.0000000000000903

Figure. Annualized relapse rate in the year before, during, and after pregnancy in rituximab, natalizumab, and untreated women (A) overall and (B) in each trimester.

Figure